Our in vitro functional assays, such as the cell cycle analysis and low BCL2 expression in Plexin-B3 knockdown cells, explain our in vivo observation of a lower tumor burden with less Ki-67-positive cells in mice injected with Plexin-B3 knockdown cells. This evidence concerns the gene PLXNB3 and neoplasm.